~~<i id='85C130F86A'><strike id='85C130F86A'><tt id='85C130F86A'><pre id='85C130F86A'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：focus 2025-09-30 04:26:27 Page View：738

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： World's first CRISPR
Next article： How to save PrEP access — and even expand it

explore

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

What to know about Virgin Galactic's 1st mission taking paying customers to space

1:42TheVirginGalacticSpaceShipTwospaceplaneUnityreturnstoearthaboveSpaceportAmerica,nearTruthandCons

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Gain of function research would be limited under House proposal

Rep.ThomasMassie(R-Ky.)KevinDietsch/GettyImagesWASHINGTON—HouselawmakerslateTuesdayvotedtoattachaU.S